

Correction: Issue and re-purchase of class C shares for shareholder program

Clarification in third paragraph (in bold)

Stockholm – February 27, 2025 – The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on difficult-to-treat cancers, has today resolved, by virtue of the authorisation by the Annual General Meeting held on 31 May 2024, to issue and immediately thereafter re-purchase a total of 10,572,577 class C shares.

The shares are issued and re-purchased in accordance with the incentive programs Co-worker LTIP 2022, Co-worker LTIP 2024 and Board SHP 2024, which were adopted by the Annual General Meetings 2022 and 2024, respectively, as well as other outstanding shareholder programs for members of the Board of Directors (the “Incentive Programs”).

DNB Bank ASA, Sweden Branch will subscribe for the entire issue of new class C shares at a subscription price of approximately SEK 0.11 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the Board of Directors’ resolution, be re-purchased **by Oncopeptides** for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of the Incentive Programs.

The purpose of the re-purchase is to ensure delivery of shares in accordance with the Incentive Programs as well as to cover any social costs due to Co-worker LTIP 2022 and Co-worker LTIP 2024. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.

For more information, please contact:

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)

E-mail: david.augustsson@oncopeptides.com

Cell phone: +46 76 229 38 68

About Oncopeptides

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com

This information is information that Oncopeptides is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-02-28 07:00 CET.

Attachments

[Issue and re-purchase of class C shares for shareholder program](#)